Smart drugs reduce quality of effort, and slow decision-making
New research on stimulants like Ritalin, amphetamines and modafinil suggests that in healthy adults they increase time-on-task and activity but often reduce the quality and efficiency of problem-solving, at least on a knapsack-style optimization test. Commenters contrast this with the real-world use of these drugs: for people with ADHD they can normalize executive function, while for others they mainly enable longer cramming or rote work rather than making anyone “smarter.” Many also question the study’s design and small sample, debate tolerance and side effects, and highlight a broader tension between pharmaceutical “enhancement” and developing sustainable focus and work habits.
What “smart drugs” are used for
- Many distinguish between medical ADHD treatment and “enhancement.”
- Non-ADHD users often take stimulants to extend study/work hours, cram, stay awake, and push through boring bulk tasks rather than to increase raw intelligence.
- Several describe them as “executive function support” or “motivation/activation” aids, not intelligence boosters.
Subjective effects and trade‑offs
- ADHD users frequently report feeling calmer, less anxious, more organized, and better able to complete routine tasks; some say meds replace chaos with predictable functioning.
- Others notice dulled creativity, more “robotic” or rote thinking, and feeling slightly “dumber” even as output increases.
- A common pattern: good for repetitive or memorization-heavy work; less obviously helpful for complex, creative, or highly conceptual tasks.
- Some report better sleep quality once focus and daytime structure improve; others report insomnia or emotional volatility, especially with modafinil or higher doses.
Tolerance, dependence, and side effects
- Multiple anecdotes of stimulants (including modafinil) “stopping working” after months or years, or needing lower expectations once the initial euphoria fades.
- Concern about tolerance, rebound, psychological dependence, and escalating doses, especially when used “as needed” for crunch periods.
- Comparisons drawn to caffeine dependence; some argue both can be managed with careful tapering and lifestyle changes, others describe severe withdrawal or long-term blunting.
- Side effects mentioned: headaches, stomach issues, racing heart, blood pressure spikes, dry skin, mood issues, and reduced appetite.
Critiques of the knapsack study
- Some question using a single-dose, small-N (40) lab task in stimulant‑naïve, “healthy” students to generalize about real-world studying or long-term use.
- Others argue an NP‑complete knapsack task is actually appropriate to show that time-on-task can increase without better solutions.
- Debate over the chosen productivity metric (value per move) vs. total score, and concern that lumping drugs together obscures differences (especially for modafinil).
Alternatives and broader context
- Diet, sleep, exercise, and avoiding constant screens or sugar are repeatedly cited as powerful non-drug levers.
- Some prefer “classic” nootropics (piracetam, noopept) or psychedelic microdosing, claiming subtler, slower benefits; evidence in the thread is mixed and largely anecdotal.
- Ethical worries: academic and workplace pressure pushing widespread stimulant use; overdiagnosis vs. underdiagnosis; and fairness between medicated and unmedicated people.